GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gen Ilac Ve Saglik Urunleri Sanayi ve Ticaret AS (IST:GENIL) » Definitions » Research & Development

Gen Ilac Veglik Urunlerinayi ve Ticaret AS (IST:GENIL) Research & Development : ₺0 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Gen Ilac Veglik Urunlerinayi ve Ticaret AS Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Gen Ilac Veglik Urunlerinayi ve Ticaret AS's Research & Development for the three months ended in Dec. 2023 was ₺0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 was ₺0 Mil.


Gen Ilac Veglik Urunlerinayi ve Ticaret AS Research & Development Historical Data

The historical data trend for Gen Ilac Veglik Urunlerinayi ve Ticaret AS's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gen Ilac Veglik Urunlerinayi ve Ticaret AS Research & Development Chart

Gen Ilac Veglik Urunlerinayi ve Ticaret AS Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial - 0.51 1.18 40.49 121.19

Gen Ilac Veglik Urunlerinayi ve Ticaret AS Quarterly Data
Dec18 Dec19 Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Gen Ilac Veglik Urunlerinayi ve Ticaret AS Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₺0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gen Ilac Veglik Urunlerinayi ve Ticaret AS  (IST:GENIL) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Gen Ilac Veglik Urunlerinayi ve Ticaret AS Research & Development Related Terms

Thank you for viewing the detailed overview of Gen Ilac Veglik Urunlerinayi ve Ticaret AS's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


Gen Ilac Veglik Urunlerinayi ve Ticaret AS (IST:GENIL) Business Description

Traded in Other Exchanges
N/A
Address
Mustafa Kemal Mahallesi 2119.Sk. No:3, Cankaya, Ankara, TUR, 06520
Gen Ilac Ve Saglik Urunleri Sanayi ve Ticaret AS is a specialty pharmaceuticals company in Turkey. Its locally manufactured products include Cajex, Contra-K, Epamor, Genkort, Ilopera, among others, while imported products include AvonexPEN, Plegridy, Tecfidera, Regen-D among others.

Gen Ilac Veglik Urunlerinayi ve Ticaret AS (IST:GENIL) Headlines

No Headlines